Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on April 25, 2025

Changing Life & Destiny Conference 2025 Kicks Off in Dallas, Uniting Leaders in Functional Health and Longevity
DALLAS, TX, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- The highly anticipated Changing Life …

Aavenir Unveils Advanced and Autonomous AI Workflows for Contract Lifecycle Management
Aavenir unveiled Contractflow Spring 2025 Release, introducing newer Gen AI capabilities that will transform how organizations work with complex contracts. MCKINNEY, TX, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- In a significant advancement …

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees …

Rezolute, Inc. Announces Closing of Underwritten Offering
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing …

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and …

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory …

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) …

Prelude Announces Presentations at 2025 AACR Annual Meeting
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, …

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications …

SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) Announces Halo Spin-Out Distribution for Stockholders of Record as of April 23, 2025
TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) (NYSE American: BTTR) (the “Company”), a leading global health and wellness company, today announced that it will distribute (the “ …

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co- …

Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development
HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived organoid model systems, is pleased to announce a strategic partnership with White Lion Capital LLC. This collaboration empowers biotech and pharma companies to leverage Spanios’ …

Clenbuterol Bodybuilding (Clen) Pills, Clenbuterol Dosage, Clenbuterol, Benefits, Clenbuterol Side Effects, Clenbuterol Cycles, Where to buy Clenbuterol tablet buy, ambroxol, lavizoo (CrazyBulk)
New York City, April 25, 2025 (GLOBE NEWSWIRE) -- Why Do People Look for Weight Loss Pills? Many people want a leaner body and look for pills to help them achieve this. One such pill is Clenbuterol, which is often used for weight loss. However, Clenbuterol …

Best Probiotics For Women: Top-Rated Picks for Digestion, Mood, and Immunity Announced By WhatBest.
New York, April 25, 2025 (GLOBE NEWSWIRE) -- WhatBest, a leading authority known for meticulous, research-based evaluations of health and wellness products, is excited to announce its comprehensive list of the best probiotics specifically chosen for women. …

Tevogen Bio Announces 2025 Annual Meeting
WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. …

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model …

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat …

Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025
Novel analytical framework establishes a clinically meaningful performance assessment of blood-based early detection tests Innovative methodology enhances cancer signal detection, boosts specificity and predictive value Presentations further validate the …